TY - JOUR
T1 - The B7 family and cancer therapy
T2 - Costimulation and coinhibition
AU - Zang, Xingxing
AU - Allison, James P.
PY - 2007/9/15
Y1 - 2007/9/15
N2 - The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.
AB - The activation and development of an adaptive immune response is initiated by the engagement of a T-cell antigen receptor by an antigenic peptide-MHCcom plex. The outcome of this engagement is determined by both positive and negative signals, costimulation and coinhibition, generated mainly by the interaction between the B7 family and their receptor CD28 family. The importance of costimulation and coinhibition of T cells in controlling immune responses is exploited by tumors as immune evasion pathways. Absence of the expression of costimulatory B7 molecules renders tumors invisible to the immune system, whereas enhanced expression of inhibitory B7 molecules protects them from effective T cell destruction. Therefore, the manipulation of these pathways is crucial for developing effective tumor immunotherapy. Translation of our basic knowledge of costimulation and coinhibition into early clinical trials has shown considerable promise.
UR - http://www.scopus.com/inward/record.url?scp=34848831575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848831575&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-1030
DO - 10.1158/1078-0432.CCR-07-1030
M3 - Review article
C2 - 17875755
AN - SCOPUS:34848831575
SN - 1078-0432
VL - 13
SP - 5271
EP - 5279
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 18
ER -